Ehlers-Danlos syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Ehlers-Danlos syndrome is a group of
connective tissue disorders that are characterized by unstable, hypermobile
joints, loose, “stretchy” skin, and tissue fragility. It is caused by a defect
in the connective tissue. The fragile tissues, stretchy skin, and unstable
joints found in Ehlers-Danlos syndrome are due to a gene mutation in collagen.
Vascular Ehlers-Danlos syndrome is an autosomal dominant condition; that is, a
child only has to inherit a defect in the COL3A1 gene from one parent to have
the disorder. About half of people with vascular Ehlers-Danlos syndrome
inherited the COL3A1 mutation from an affected parent. The other half of people
with the condition have a spontaneous disease-causing mutation; that is, they
are the first person in their family to have vascular Ehlers-Danlos syndrome.
Each child of an affected parent has a 50 percent chance of inheriting the
mutation and developing the disorder.
- The estimated prevalence of Ehlers-Danlos syndrome is 1 in
every 5,000 birth
Thelansis’s “Ehlers-Danlos syndrome Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Ehlers-Danlos
syndrome treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Ehlers-Danlos syndrome across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Ehlers-Danlos syndrome Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment